KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2025)

Recursion Pharmaceuticals' Operating Leases history spans 4 years, with the latest figure at $77.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 15.46% year-over-year to $77.6 million; the TTM value through Dec 2025 reached $77.6 million, up 15.46%, while the annual FY2025 figure was $77.6 million, 15.46% up from the prior year.
  • Operating Leases reached $77.6 million in Q4 2025 per RXRX's latest filing, up from $50.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $88.8 million in Q2 2024 to a low of $44.4 million in Q4 2022.
  • Average Operating Leases over 4 years is $55.6 million, with a median of $51.1 million recorded in 2023.
  • Peak YoY movement for Operating Leases: skyrocketed 73.82% in 2024, then crashed 39.85% in 2025.
  • A 4-year view of Operating Leases shows it stood at $44.4 million in 2022, then increased by 11.5% to $49.5 million in 2023, then surged by 35.78% to $67.2 million in 2024, then rose by 15.46% to $77.6 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Operating Leases are $77.6 million (Q4 2025), $50.0 million (Q3 2025), and $53.4 million (Q2 2025).